Home LiteratureArticle Details
PMID: 19629069 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Signal integration by JNK and p38 MAPK pathways in cancer development.

Nature reviews. Cancer ·Vol. 9 ·No. 8 ·2009-08-00 ·Pages 537-49

Wagner EF, Nebreda AR

Abstract

Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) family members function in a cell context-specific and cell type-specific manner to integrate signals that affect proliferation, differentiation, survival and migration. Consistent with the importance of these events in tumorigenesis, JNK and p38 MAPK signalling is associated with cancers in humans and mice. Studies in mouse models have been essential to better understand how these MAPKs control cancer development, and these models are expected to provide new strategies for the design of improved therapeutic approaches. In this Review we highlight the recent progress made in defining the functions of the JNK and p38 MAPK pathways in different cancers.

MeSH Terms
Animals Apoptosis Cell Proliferation Disease Models, Animal Humans JNK Mitogen-Activated Protein Kinases/physiology MAP Kinase Signaling System/physiology Mice Neoplasms/etiology,pathology,therapy Receptor Cross-Talk p38 Mitogen-Activated Protein Kinases/physiology
Chemicals
JNK Mitogen-Activated Protein Kinases p38 Mitogen-Activated Protein Kinases
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Wagner Erwin F
Centro Nacional de Investigaciones Oncológicas, C/Melchor Fernández Almagro 3, Madrid 28029, Spain. ewagner@cnio.es
Nebreda Angel R
References (161)
161 references, click to expand
  1. Identification of a new JNK inhibitor targeting the JNK-JIP interaction site.
    Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16809-13 PMID: 18922779
  2. MAPKAPK-2-mediated LIM-kinase activation is critical for VEGF-induced actin remodeling and cell migration.
    EMBO J. 2006 Feb 22;25(4):713-26 PMID: 16456544
  3. Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma.
    Cancer. 2003 Jun 15;97(12):3017-26 PMID: 12784337
  4. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma.
    Cancer Res. 2006 Feb 15;66(4):2264-70 PMID: 16489030
  5. Essential role for p38alpha mitogen-activated protein kinase in placental angiogenesis.
    Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10454-9 PMID: 10973481
  6. Models, mechanisms and clinical evidence for cancer dormancy.
    Nat Rev Cancer. 2007 Nov;7(11):834-46 PMID: 17957189
  7. Targeting the mitogen-activated protein kinase cascade to treat cancer.
    Nat Rev Cancer. 2004 Dec;4(12):937-47 PMID: 15573115
  8. Patterns of somatic mutation in human cancer genomes.
    Nature. 2007 Mar 8;446(7132):153-8 PMID: 17344846
  9. p38 mitogen-activated protein kinase pathway is involved in protein kinase Calpha-regulated invasion in human hepatocellular carcinoma cells.
    Cancer Res. 2007 May 1;67(9):4320-7 PMID: 17483345
  10. c-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity.
    Genes Dev. 2006 Aug 15;20(16):2306-14 PMID: 16912279
  11. Gadd45a suppresses Ras-driven mammary tumorigenesis by activation of c-Jun NH2-terminal kinase and p38 stress signaling resulting in apoptosis and senescence.
    Cancer Res. 2006 Sep 1;66(17):8448-54 PMID: 16951155
  12. Selective p38 activation in human non-small cell lung cancer.
    Am J Respir Cell Mol Biol. 2002 May;26(5):558-64 PMID: 11970907
  13. The JNK signal transduction pathway.
    Curr Opin Cell Biol. 2007 Apr;19(2):142-9 PMID: 17303404
  14. Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer.
    J Hepatol. 2009 Feb;50(2):323-33 PMID: 19041150
  15. The c-jun kinase/stress-activated pathway: regulation, function and role in human disease.
    Biochim Biophys Acta. 2007 Aug;1773(8):1341-8 PMID: 17306896
  16. Regulation of the immune response by stress-activated protein kinases.
    Immunol Rev. 2009 Mar;228(1):212-24 PMID: 19290930
  17. The kinase p38 alpha serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression.
    Nat Immunol. 2008 Sep;9(9):1019-27 PMID: 18677317
  18. Involvement of p38alpha mitogen-activated protein kinase in lung metastasis of tumor cells.
    J Biol Chem. 2006 Dec 1;281(48):36767-75 PMID: 17028194
  19. Feedback control of the protein kinase TAK1 by SAPK2a/p38alpha.
    EMBO J. 2003 Nov 3;22(21):5793-805 PMID: 14592977
  20. p38 MAP kinase signaling is necessary for rat chondrosarcoma cell proliferation.
    Oncogene. 2004 Apr 29;23(20):3726-31 PMID: 15116104
  21. Post-transcriptional regulation of gene expression by mitogen-activated protein kinase p38.
    FEBS Lett. 2003 Jul 3;546(1):37-44 PMID: 12829234
  22. A JNK-dependent pathway is required for TNFalpha-induced apoptosis.
    Cell. 2003 Oct 3;115(1):61-70 PMID: 14532003
  23. Induction of hepatitis by JNK-mediated expression of TNF-alpha.
    Cell. 2009 Jan 23;136(2):249-60 PMID: 19167327
  24. Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts.
    Nat Genet. 2002 Sep;32(1):201-5 PMID: 12161751
  25. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis.
    Cancer Cell. 2008 Aug 12;14(2):156-65 PMID: 18691550
  26. Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: a MLK-3-MKK7-dependent mechanism.
    Cell Signal. 2008 Apr;20(4):675-83 PMID: 18222647
  27. p38 alpha MAPK inhibits JNK activation and collaborates with IkappaB kinase 2 to prevent endotoxin-induced liver failure.
    EMBO Rep. 2008 Oct;9(10):1048-54 PMID: 18704119
  28. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy.
    Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7259-64 PMID: 12756297
  29. UVA-mediated activation of signaling pathways involved in skin tumor promotion and progression.
    Semin Cancer Biol. 2004 Apr;14(2):131-8 PMID: 15018897
  30. Map kinase signaling pathways and hematologic malignancies.
    Blood. 2003 Jun 15;101(12):4667-79 PMID: 12623839
  31. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance.
    Science. 2008 Dec 5;322(5907):1539-43 PMID: 19056984
  32. Hepatocyte survival in acute hepatitis is due to c-Jun/AP-1-dependent expression of inducible nitric oxide synthase.
    Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17105-10 PMID: 17940019
  33. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway.
    Science. 2000 May 5;288(5467):870-4 PMID: 10797012
  34. Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer.
    Science. 2009 Feb 27;323(5918):1218-22 PMID: 19164706
  35. Selective interaction of JNK protein kinase isoforms with transcription factors.
    EMBO J. 1996 Jun 3;15(11):2760-70 PMID: 8654373
  36. p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells.
    Cancer Res. 2003 Sep 1;63(17):5454-61 PMID: 14500381
  37. The p38 transduction pathway in prostatic neoplasia.
    J Pathol. 2006 Feb;208(3):401-7 PMID: 16369914
  38. High-level expression, activation, and subcellular localization of p38-MAP kinase in thyroid neoplasms.
    J Pathol. 2006 Jul;209(3):298-306 PMID: 16583356
  39. p38delta Mitogen-activated protein kinase is essential for skin tumor development in mice.
    Cancer Res. 2009 Jun 1;69(11):4648-55 PMID: 19458068
  40. Induction of apoptosis by SB202190 through inhibition of p38beta mitogen-activated protein kinase.
    J Biol Chem. 1998 Jun 26;273(26):16415-20 PMID: 9632706
  41. Suppression of p53-dependent senescence by the JNK signal transduction pathway.
    Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15759-64 PMID: 17893331
  42. CXCL12 and C5a trigger cell migration via a PAK1/2-p38alpha MAPK-MAPKAP-K2-HSP27 pathway.
    Cell Signal. 2006 Nov;18(11):1897-905 PMID: 16574378
  43. Opposing effects of Jun kinase and p38 mitogen-activated protein kinases on cardiomyocyte hypertrophy.
    Mol Cell Biol. 1998 Jun;18(6):3518-26 PMID: 9584192
  44. Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation.
    Stem Cells. 2006 Jan;24(1):23-33 PMID: 16100005
  45. Mechanism of p38 MAP kinase activation in vivo.
    Genes Dev. 2003 Aug 15;17(16):1969-78 PMID: 12893778
  46. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway.
    Nat Genet. 2007 Jun;39(6):741-9 PMID: 17468757
  47. The p38 MAPK stress pathway as a tumor suppressor or more?
    Front Biosci. 2008 May 01;13:3581-93 PMID: 18508457
  48. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation.
    Physiol Rev. 2001 Apr;81(2):807-69 PMID: 11274345
  49. Role of mitogen-activated protein kinase kinase kinases in signal integration.
    Oncogene. 2007 May 14;26(22):3159-71 PMID: 17496913
  50. p38gamma regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP.
    EMBO J. 2005 Mar 23;24(6):1134-45 PMID: 15729360
  51. Requirement for p38alpha in erythropoietin expression: a role for stress kinases in erythropoiesis.
    Cell. 2000 Jul 21;102(2):221-31 PMID: 10943842
  52. The antiapoptotic effect of heme oxygenase-1 in endothelial cells involves the degradation of p38 alpha MAPK isoform.
    J Immunol. 2006 Aug 1;177(3):1894-903 PMID: 16849502
  53. Role of mitogen-activated protein kinase kinase 4 in cancer.
    Oncogene. 2007 May 14;26(22):3172-84 PMID: 17496914
  54. The c-Jun NH2-terminal kinase3 (JNK3) gene: genomic structure, chromosomal assignment, and loss of expression in brain tumors.
    J Hum Genet. 2001;46(4):182-7 PMID: 11322657
  55. Gadd45 beta mediates the NF-kappa B suppression of JNK signalling by targeting MKK7/JNKK2.
    Nat Cell Biol. 2004 Feb;6(2):146-53 PMID: 14743220
  56. JNK2: a negative regulator of cellular proliferation.
    Cell Cycle. 2004 Dec;3(12):1520-3 PMID: 15611655
  57. Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1.
    Oncogene. 2002 Feb 7;21(7):1000-8 PMID: 11850817
  58. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation.
    Science. 2008 May 2;320(5876):667-70 PMID: 18451303
  59. Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7.
    Cancer Res. 2005 Dec 1;65(23):10984-91 PMID: 16322247
  60. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis.
    Cell. 2005 Jul 1;121(7):977-90 PMID: 15989949
  61. TNF-alpha induces two distinct caspase-8 activation pathways.
    Cell. 2008 May 16;133(4):693-703 PMID: 18485876
  62. pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells.
    J Biol Chem. 1999 Mar 12;274(11):7341-50 PMID: 10066798
  63. Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer.
    Cancer Res. 2008 Apr 1;68(7):2132-44 PMID: 18381418
  64. A novel cell type-specific role of p38alpha in the control of autophagy and cell death in colorectal cancer cells.
    Cell Death Differ. 2007 Apr;14(4):693-702 PMID: 17159917
  65. c-Jun N-terminal kinases as potential therapeutic targets.
    Expert Opin Ther Targets. 2007 Oct;11(10):1339-53 PMID: 17907963
  66. Differential effects of JNK1 and JNK2 on signal specific induction of apoptosis.
    Oncogene. 2002 Apr 4;21(15):2441-5 PMID: 11948429
  67. Suppression of p38-stress kinase sensitizes quiescent leukemic cells to anti-mitotic drugs by inducing proliferative responses in them.
    Cancer Biol Ther. 2008 Aug;7(8):1232-40 PMID: 18487954
  68. JNK phosphorylates paxillin and regulates cell migration.
    Nature. 2003 Jul 10;424(6945):219-23 PMID: 12853963
  69. Distinct carboxy-termini confer divergent characteristics to the mitogen-activated protein kinase p38alpha and its splice isoform Mxi2.
    FEBS Lett. 2000 Jun 2;474(2-3):169-74 PMID: 10838079
  70. Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling.
    Mol Cell Biol. 2005 Jun;25(12):4853-62 PMID: 15923604
  71. c-Jun NH2-terminal kinase 1 plays a critical role in intestinal homeostasis and tumor suppression.
    Am J Pathol. 2007 Jul;171(1):297-303 PMID: 17591974
  72. Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2.
    Cancer Cell. 2006 Jun;9(6):445-57 PMID: 16766264
  73. The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis.
    Oncogene. 2007 Apr 12;26(17):2502-6 PMID: 17016428
  74. A novel role of p38 alpha MAPK in mitotic progression independent of its kinase activity.
    Cell Cycle. 2005 Nov;4(11):1616-24 PMID: 16258274
  75. The role of the transcription factor AP-1 in colitis-associated and beta-catenin-dependent intestinal tumorigenesis in mice.
    Oncogene. 2008 Oct 16;27(47):6102-9 PMID: 18679426
  76. The pathways to tumor suppression via route p38.
    Trends Biochem Sci. 2007 Aug;32(8):364-71 PMID: 17624785
  77. PRAK is essential for ras-induced senescence and tumor suppression.
    Cell. 2007 Jan 26;128(2):295-308 PMID: 17254968
  78. Macrophage deletion of p38alpha partially impairs lipopolysaccharide-induced cellular activation.
    J Immunol. 2008 Apr 1;180(7):5075-82 PMID: 18354233
  79. p38/RK is essential for stress-induced nuclear responses: JNK/SAPKs and c-Jun/ATF-2 phosphorylation are insufficient.
    Curr Biol. 1996 Aug 1;6(8):1028-31 PMID: 8805335
  80. Cell cycle regulation by p38 MAP kinases.
    Biol Cell. 2001 Sep;93(1-2):47-51 PMID: 11730321
  81. Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate.
    Cancer Res. 2002 Mar 1;62(5):1343-8 PMID: 11888903
  82. A selective small-molecule inhibitor of c-Jun N-terminal kinase 1.
    FEBS Lett. 2009 Jul 7;583(13):2208-12 PMID: 19527717
  83. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway.
    Nat Genet. 2004 Apr;36(4):343-50 PMID: 14991053
  84. Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development.
    Mol Cell. 2000 Jul;6(1):109-16 PMID: 10949032
  85. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
    Cancer. 2004 Feb 1;100(3):499-506 PMID: 14745865
  86. AP-1: a double-edged sword in tumorigenesis.
    Nat Rev Cancer. 2003 Nov;3(11):859-68 PMID: 14668816
  87. RhoA-ROCK and p38MAPK-MSK1 mediate vitamin D effects on gene expression, phenotype, and Wnt pathway in colon cancer cells.
    J Cell Biol. 2008 Nov 17;183(4):697-710 PMID: 19015318
  88. Cancer-related inflammation.
    Nature. 2008 Jul 24;454(7203):436-44 PMID: 18650914
  89. Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development.
    Nature. 2005 Sep 8;437(7056):281-5 PMID: 16007074
  90. Oncogenic K-Ras down-regulates Rac1 and RhoA activity and enhances migration and invasion of pancreatic carcinoma cells through activation of p38.
    Cell Signal. 2006 Aug;18(8):1156-68 PMID: 16257181
  91. The p38 signal transduction pathway: activation and function.
    Cell Signal. 2000 Jan;12(1):1-13 PMID: 10676842
  92. Mammalian MAP kinase signalling cascades.
    Nature. 2001 Mar 1;410(6824):37-40 PMID: 11242034
  93. Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice.
    Cancer Res. 2001 May 15;61(10):3908-12 PMID: 11358804
  94. JNK signalling modulates intestinal homeostasis and tumourigenesis in mice.
    EMBO J. 2009 Jul 8;28(13):1843-54 PMID: 19521338
  95. Activation of p38 has opposing effects on the proliferation and migration of endothelial cells.
    J Biol Chem. 2005 Jun 3;280(22):20995-1003 PMID: 15790570
  96. p38 MAP kinase's emerging role as a tumor suppressor.
    Adv Cancer Res. 2004;92:95-118 PMID: 15530558
  97. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease.
    Cell. 2008 Sep 5;134(5):743-56 PMID: 18775308
  98. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia.
    Nat Med. 2003 Sep;9(9):1180-6 PMID: 12937412
  99. Generation and characterization of p38beta (MAPK11) gene-targeted mice.
    Mol Cell Biol. 2005 Dec;25(23):10454-64 PMID: 16287858
  100. p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis.
    Cancer Cell. 2007 Feb;11(2):191-205 PMID: 17292829
  101. Regulation of MAP kinase signaling modules by scaffold proteins in mammals.
    Annu Rev Cell Dev Biol. 2003;19:91-118 PMID: 14570565
  102. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.
    Cancer Cell. 2007 Feb;11(2):175-89 PMID: 17292828
  103. p38alpha: a suppressor of cell proliferation and tumorigenesis.
    Cell Cycle. 2007 Oct 15;6(20):2429-33 PMID: 17957136
  104. Involvement of the MKK6-p38gamma cascade in gamma-radiation-induced cell cycle arrest.
    Mol Cell Biol. 2000 Jul;20(13):4543-52 PMID: 10848581
  105. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases.
    Cell. 2005 Mar 11;120(5):649-61 PMID: 15766528
  106. Chemical genetic analysis of the time course of signal transduction by JNK.
    Mol Cell. 2006 Mar 3;21(5):701-10 PMID: 16507367
  107. Inhibitors of c-Jun N-terminal kinases: JuNK no more?
    Biochim Biophys Acta. 2008 Jan;1784(1):76-93 PMID: 17964301
  108. The JNK pathway regulates the In vivo deletion of immature CD4(+)CD8(+) thymocytes.
    J Exp Med. 1998 Nov 16;188(10):1817-30 PMID: 9815259
  109. Embryonic stem cells utilize reactive oxygen species as transducers of mechanical strain-induced cardiovascular differentiation.
    FASEB J. 2006 Jun;20(8):1182-4 PMID: 16636108
  110. Function of JunB in transient amplifying cell senescence and progression of human prostate cancer.
    Clin Cancer Res. 2008 Jul 15;14(14):4408-16 PMID: 18628455
  111. JNK2 is a positive regulator of the cJun transcription factor.
    Mol Cell. 2006 Sep 15;23(6):899-911 PMID: 16973441
  112. IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha.
    Immunity. 2003 Nov;19(5):725-37 PMID: 14614859
  113. c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice.
    Cancer Res. 2008 Jul 1;68(13):5031-9 PMID: 18593901
  114. Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo.
    J Biol Chem. 2004 Apr 9;279(15):15524-30 PMID: 14749328
  115. MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival.
    Mol Cancer Ther. 2007 Apr;6(4):1212-22 PMID: 17406030
  116. The functional contrariety of JNK.
    Mol Carcinog. 2007 Aug;46(8):591-8 PMID: 17538955
  117. Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38alpha in abrogating myoblast proliferation.
    EMBO J. 2007 Mar 7;26(5):1245-56 PMID: 17304211
  118. Nuclear factor-kappaB in cancer development and progression.
    Nature. 2006 May 25;441(7092):431-6 PMID: 16724054
  119. Beyond apoptosis of JNK1 in liver cancer.
    Cell Cycle. 2009 Apr 15;8(8):1145-7 PMID: 19270500
  120. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms.
    J Cell Sci. 2002 Nov 15;115(Pt 22):4317-25 PMID: 12376563
  121. p38alpha, but not p38beta, inhibits the phosphorylation and presence of c-FLIPS in DISC to potentiate Fas-mediated caspase-8 activation and type I apoptotic signaling.
    J Cell Sci. 2004 Dec 15;117(Pt 26):6459-71 PMID: 15572410
  122. p38 MAP kinase: a convergence point in cancer therapy.
    Trends Mol Med. 2004 Mar;10(3):125-9 PMID: 15102355
  123. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23.
    Nat Genet. 2002 Jun;31(2):133-4 PMID: 12021784
  124. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN.
    Cancer Cell. 2007 Jun;11(6):555-69 PMID: 17560336
  125. p38 MAP-kinases pathway regulation, function and role in human diseases.
    Biochim Biophys Acta. 2007 Aug;1773(8):1358-75 PMID: 17481747
  126. p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation.
    Nat Genet. 2007 Jun;39(6):750-8 PMID: 17468755
  127. Antagonistic control of cell fates by JNK and p38-MAPK signaling.
    Cell Death Differ. 2008 Jan;15(1):89-93 PMID: 17762881
  128. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover.
    Cell. 2006 Feb 10;124(3):601-13 PMID: 16469705
  129. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis.
    Nature. 1994 Dec 22-29;372(6508):739-46 PMID: 7997261
  130. Activating p38 MAPK: new tricks for an old kinase.
    Cell Cycle. 2005 Sep;4(9):1189-92 PMID: 16103752
  131. p38 MAP kinases: beyond the stress response.
    Trends Biochem Sci. 2000 Jun;25(6):257-60 PMID: 10838561
  132. Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells.
    Oncogene. 2002 Jul 4;21(29):4567-76 PMID: 12085235
  133. Phosphorylation-dependent targeting of c-Jun ubiquitination by Jun N-kinase.
    Oncogene. 1996 Oct 3;13(7):1531-5 PMID: 8875991
  134. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer.
    Br J Cancer. 2006 Apr 24;94(8):1154-63 PMID: 16570043
  135. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation.
    J Clin Invest. 2008 Dec;118(12):3943-53 PMID: 19033664
  136. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation.
    Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10544-51 PMID: 16807293
  137. A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity.
    Oncogene. 2007 Feb 22;26(8):1178-87 PMID: 16924234
  138. Elimination of protein kinase MK5/PRAK activity by targeted homologous recombination.
    Mol Cell Biol. 2003 Nov;23(21):7732-41 PMID: 14560018
  139. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation.
    Mol Cell. 2004 Sep 10;15(5):713-25 PMID: 15350216
  140. Regulation of skeletal muscle gene expression by p38 MAP kinases.
    Trends Cell Biol. 2006 Jan;16(1):36-44 PMID: 16325404
  141. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis.
    Nat Cell Biol. 2006 Dec;8(12):1369-75 PMID: 17128264
  142. From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance.
    IUBMB Life. 2005 Apr-May;57(4-5):283-95 PMID: 16036612
  143. Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells.
    Genes Dev. 2000 Mar 1;14(5):574-84 PMID: 10716945
  144. Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis.
    Science. 2004 Nov 26;306(5701):1558-61 PMID: 15567863
  145. p38 mitogen-activated protein kinase activity commits embryonic stem cells to either neurogenesis or cardiomyogenesis.
    Stem Cells. 2006 May;24(5):1399-406 PMID: 16424397
  146. EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas.
    Cancer Res. 2007 Jul 1;67(13):6121-9 PMID: 17616668
  147. Regulation of the JNK pathway by TGF-beta activated kinase 1 in rheumatoid arthritis synoviocytes.
    Arthritis Res Ther. 2007;9(3):R57 PMID: 17559674
  148. The promise of retinoids to fight against cancer.
    Nat Rev Cancer. 2001 Dec;1(3):181-93 PMID: 11902573
  149. p38alpha and p38delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells.
    Oncogene. 2007 Aug 9;26(36):5267-79 PMID: 17334397
  150. p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes.
    Genes Dev. 2005 May 15;19(10):1175-87 PMID: 15870258
  151. Feedback regulation of p38 activity via ATF2 is essential for survival of embryonic liver cells.
    Genes Dev. 2007 Aug 15;21(16):2069-82 PMID: 17699753
  152. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.
    Science. 2008 Sep 26;321(5897):1801-6 PMID: 18772397
  153. Daphnetin induced differentiation of human renal carcinoma cells and its mediation by p38 mitogen-activated protein kinase.
    Biochem Pharmacol. 2004 May 1;67(9):1779-88 PMID: 15081877
  154. Chemical genetics define the roles of p38alpha and p38beta in acute and chronic inflammation.
    J Biol Chem. 2007 Nov 30;282(48):34663-71 PMID: 17855341
  155. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
    Nat Genet. 2002 Jun;31(2):210-5 PMID: 12021785
  156. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53.
    Cell. 2003 Jan 24;112(2):181-92 PMID: 12553907
  157. Non-classical p38 map kinase functions: cell cycle checkpoints and survival.
    Int J Biol Sci. 2009;5(1):44-51 PMID: 19159010
  158. MAP kinase pathways: the first twenty years.
    Biochim Biophys Acta. 2007 Aug;1773(8):1150-60 PMID: 17229475
  159. Gadd45beta promotes hepatocyte survival during liver regeneration in mice by modulating JNK signaling.
    J Clin Invest. 2008 May;118(5):1911-23 PMID: 18382767
  160. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases.
    Nat Rev Drug Discov. 2003 Sep;2(9):717-26 PMID: 12951578
  161. Regulation of PKD by the MAPK p38delta in insulin secretion and glucose homeostasis.
    Cell. 2009 Jan 23;136(2):235-48 PMID: 19135240
Article Info
Journal
Nature reviews. Cancer
Abbr.
Nat Rev Cancer
ISSN
1474-1768
DOI
10.1038/nrc2694
Email
ewagner@cnio.es
Published
2009-08-00
Pages
537-49
Language
English
Region
England
NLM ID
101124168
Subset
IM
External Links
PubMed source DOI: 10.1038/nrc2694 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2